Posts by: Alice Melão

News

Dutch researchers have developed a new experimental protocol that allowed them to culture mini ovarian cancers (organoids) in the lab that retained their three-dimensional structure and captured the cellular ... Read more

April 29, 2019

Ovarian Cancer Patients Being Recruited to Test HPN536 Immunotherapy in Phase 1/2a Trial

News

Harpoon Therapeutics has begun dosing participants in its Phase 1/2a trial evaluating the investigational immunotherapy HPN536 in patients with advanced cancers that produce the mesothelin protein. The study (NCT03872206) ... Read more

April 3, 2019

DPX-Survivac Treatment Continues to Show Promise in Women with Advanced Ovarian Cancer, Early Data Show

News

Treatment with DPX-Survivac plus intermittent low-dose cyclophosphamide continues to show promise in women with advanced recurrent ovarian cancer, the second part of a Phase 1/2 trial shows. Interim data ... Read more

March 6, 2019

FPA150 Trial Begins Dosing Ovarian, Breast, Endometrial Cancer Patients

News

Five Prime Therapeutics’ ongoing Phase 1 clinical trial has advanced to its Phase 1b expansion portion, in which researchers have begun giving breast, ovarian, and endometrial cancer patients an optimal ... Read more

March 4, 2019

Phase 2 Trial Completes Dosing First OC Patient with Aivita’s Cell Therapy

News

A Phase 2 trial exploring Aivita Biomedical’s cell therapy AVOVA-1 for ovarian cancer has treated its first patient and continues to recruit participants across eight sites in the United States. So ... Read more

March 1, 2019

UPMC Trial to Explore Ampligen Combo for Recurrent Ovarian Cancer

News

A new investigator-sponsored clinical trial is recruiting women with recurrent, platinum-sensitive ovarian cancer to study a combination of Hemispherx Biopharma’s investigational product Ampligen (rintatolimod) plus chemo-immunotherapy, the company announced. The Phase 1/2 ... Read more

February 15, 2019

1st Patient Dosed in Phase 1/2 Trial of COTI-2 Plus Chemo for Gynecological and Other Solid Cancers

News

A first patient has been given a combination of an investigational therapy, COTI-2, plus standard-of-care chemotherapy in an expanded Phase 1b/2a trial for gynecological and other solid tumors, Cotinga ... Read more

January 4, 2019

Lynparza Approved in U.S. as First-line Maintenance Therapy for BRCA-positive Advanced Ovarian Cancer

News

Women with BRCA-mutated advanced ovarian cancer living in the United States can now receive Lynparza (olaparib), developed by AstraZeneca and Merck, as a maintenance treatment for their partial or complete response to ... Read more

November 12, 2018

Docetaxel Nanoparticle CPC634 in Phase 2 Trial for Platinum-resistant OC

News

Cristal Therapeutics has begun patient dosing in its Phase 2a trial evaluating CPC634 — the chemotherapy docetaxel, delivered in nanoparticles — in patients whose ovarian cancer has become resistant to ... Read more

October 26, 2018

Five Prime’s Phase 1 Trial Begins FPA150 Dosing Among Solid Tumor Patients

News

The Phase 1a/1b trial evaluating Five Prime Therapeutics‘ checkpoint inhibitor FPA150 in patients with advanced solid cancers has begun dosing patients ahead of schedule, the company announced. FPA150 is an antibody ... Read more

Posts by: Alice Melão

Alice Melão

Dutch Researchers Develop Mini Ovarian Cancers to Improve Personalized Therapies

Ovarian Cancer Patients Being Recruited to Test HPN536 Immunotherapy in Phase 1/2a Trial

DPX-Survivac Treatment Continues to Show Promise in Women with Advanced Ovarian Cancer, Early Data Show

FPA150 Trial Begins Dosing Ovarian, Breast, Endometrial Cancer Patients

Phase 2 Trial Completes Dosing First OC Patient with Aivita’s Cell Therapy

UPMC Trial to Explore Ampligen Combo for Recurrent Ovarian Cancer

1st Patient Dosed in Phase 1/2 Trial of COTI-2 Plus Chemo for Gynecological and Other Solid Cancers

Lynparza Approved in U.S. as First-line Maintenance Therapy for BRCA-positive Advanced Ovarian Cancer

Docetaxel Nanoparticle CPC634 in Phase 2 Trial for Platinum-resistant OC

Five Prime’s Phase 1 Trial Begins FPA150 Dosing Among Solid Tumor Patients

Pin It on Pinterest